Diseases Home > Ilaris and Breastfeeding
It is thought that Ilaris (canakinumab) would pass through breast milk, although it is unknown what effects it might have on a nursing infant. The drug is a manufactured version of an antibody that is found naturally in the body and is known to pass through breast milk in small amounts. To avoid potential risks, talk to your healthcare provider before receiving Ilaris while breastfeeding.
Can Breastfeeding Women Receive Ilaris?
Ilaris® (canakinumab) is a prescription medication approved for use in adults and children who are at least four years old who have a hereditary condition known as cryopyrin-associated periodic syndrome. It is also approved for systemic juvenile idiopathic arthritis (SJIA).
At this time, it is unknown if Ilaris passes through breast milk. If you are nursing a child, talk with your healthcare provider before taking this medication.
More Information on Ilaris and BreastfeedingNo research has been done on Ilaris and breastfeeding. Therefore, it is unknown whether the medicine passes through breast milk, or whether it would harm a nursing child. Although this lack of information is certainly frustrating, it is important to understand that studies of medications are rarely done in breastfeeding women, as this could expose an infant who will not directly benefit from the medication to possible risks.
Ilaris is a manufactured form of immunoglobulin G (IgG), an antibody that is made by the immune system and normally found in the body. IgG is known to pass through breast milk in small amounts, so it is likely that Ilaris would also pass through breast milk. However, the amount that would be expected in breast milk and the effects on a nursing infant are unknown.